Open AccessPredictors of Sustained Response to Rivastigmine in Patients With Alzheimer’s Disease
Author(s) -
Carl Sadowsky,
George T. Grossberg,
Monique Somogyi,
Xiangyi Meng
Publication year - 2011
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.328
H-Index - 50
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.10m01101
Subject(s) - rivastigmine , medicine , placebo , donepezil , dementia , activities of daily living , alzheimer's disease , disease , physical therapy , pathology , alternative medicine
The cholinesterase inhibitor rivastigmine is approved for the treatment of mild to moderate Alzheimer's disease. However, it is not possible to predict which individuals will benefit from treatment. This retrospective analysis of an international, 24-week, randomized, double-blind trial aimed to identify the percentage of persons with Alzheimer's disease who have a sustained response with rivastigmine patch, rivastigmine capsules, or placebo; to determine the magnitude of the sustained treatment response; and to investigate baseline patient characteristics predictive of the observed sustained response.